A Phase I, Multicenter, Open-label, safety of Human Cord Blood Derived, Culture-Expanded, Natural Killer Cell (PNK-007) Infusion with subcutaneous Recombinant Human IL-2 (RHIL-2) following autologous stem cell transplant for Multiple Myeloma
|Effective start/end date||10/20/16 → 12/31/20|
- Celgene Corporation
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.